leaderboard background final minSlide thumbnail
Please See The Press Release.

This acquisition will offer clients with an integrated solution to help accelerate their gene therapy programs from discovery, non-clinical/clinical development through commercialization.

Charles River Laboratories to Acquire Vigene

Welcome to Vigene Biosciences

Since our founding in 2012, Vigene Biosciences has been a leader at the forefront of cell and gene therapy, Adeno-Associated virus or AAV vector production, adenovirus vector production, lentivirus vector production, retrovirus vector production, plasmid production, viral vector QC and analytical services, plasmid QC and analytical services, providing services and products to support this rapidly growing and increasingly important field. Our diverse, international team is made up of molecular biologists, virologists, chemical and biomedical engineers, quality control professionals, and quality assurance professionals as well support staff, all of whom are dedicated to helping our customers perform groundbreaking research.

As an award-winning world leader in plasmid and viral vector development and manufacturing, Vigene serves a diverse client base that includes thousands of scientists all across the world in a number of different settings, including:

● Academia
● Government organizations
● Research Institutes
● Biotechnology companies
● Pharmaceutical companies

 

At Vigene, we strive to ensure that gene therapy is not only possible, but affordable as well. We are a global leader in providing integrated services, superior gene delivery technologies, and manufacturing solutions. Our goal is to help cell and gene therapy innovators develop and launch successful cell and gene therapies, vaccines, diagnostics and health products.

We believe our mission, Make Gene Therapy Affordable, enables our customers to make the world healthier, cleaner, and safer. We achieve this by helping our customers accelerate life sciences research, which leads to increased laboratory productivity and helps deliver medicines to market. As innovators, we’re constantly striving to improve our processes so we can help you improve your results.

AAV Gene Delivery

AAV

For tissue specificity and low immunogenicity in vivo.

AAV Packaging Services >
cGMP AAV Production >

Adenovirus Gene Delivery

Adenovirus

For a large packaging capacity and high transduction efficiency.

Adenovirus Packaging Services >
cGMP Adenovirus Production >

Lentivirus Gene Delivery

Lentivirus

For strong and stable gene expression.

Lentivirus Packaging Services >
cGMP Lentivirus Production >

Popular Services

Top Product Categories

Custom Production and Packaging Services

At Vigene, we know there is no single production method or packaging strategy that is effective for every project, and that different types of plasmid are required at different stages of development. That’s why we offer custom packaging and production solutions for our customers. We can tailor our viral services to meet your needs.

AAV Production and Packaging

Recombinant adeno-associated virus (AAV) has become a popular viral vector for gene therapy for a number of reasons. The key value of AAVs is their versatility, making them ideal for in vitro and in vivo gene delivery. AAVs transduce a wide variety of mammalian cell types, while their non-pathogenicity and low immunogenicity in humans minimize risk.

Recombinant adeno-associated virus (AAV) has become a popular viral vector for gene therapy for a number of reasons. The key value of AAVs is their versatility, making them ideal for in vitro and in vivo gene delivery. AAVs transduce a wide variety of mammalian cell types, while their non-pathogenicity and low immunogenicity in humans minimize risk.

There are several advantages to using AAV as a viral vector, including:

● Easily manipulated
● Allows protein expression for long periods
● Never shown to cause disease
● Works in both dividing and non-dividing cells

 

At our facility, we can produce ultra-purified AAV viral vectors of several serotypes, including AAV1, AAV2, AAV5, AAV6, AAV8, AAV9, AAV-DJ, AAV-PHP. We can also produce AAV viral vectors using helper viruses, or in Sf9 Baculovirus system, or in our HEK293 helper-free transient transfection system.

Services at Vigene are fully integrated, from custom vector production and plasmid prep to viral vector production. This allows us to provide our customers a seamless, streamlined process, from project design through manufacturing.

 

Adenovirus Vector Production and Packaging

Wild-type adenoviruses are responsible for a number of mild illnesses in humans, especially upper respiratory infections. However, by deleting the two genes responsible for viral replication and modulating host immune response, recombinant adenoviruses can become excellent viral vectors for gene therapy.

Recombinant adenoviral vectors effectively achieve high levels of transgene expression across a broad range of mammalian cell types in which the vector persists as episomal DNA without integrating into the host genome.

Adenoviral vectors are a preferred mechanism for in vivo gene therapy, thanks to their high levels of short-term gene expression and high transduction efficiency. It’s for this reason they’re often used in gene therapy and vaccinations.

When deciding on the right viral vector for your project, consider these qualities of recombinant adenoviruses:

● High efficiency infecting mammalian cells
● Transient, high level gene expression
● Effective in both in vivo and in vitro settings
● Remains as episomal DNA, leaving host genome untouched

 

At Vigene, we cater to all scientific needs. Our adenovirus services include small scale adenovirus packaging for in vitro work, large-scale adenovirus packaging for animal studies, and cGMP production for use in clinical applications.

 

Lentivirus Vector Production and Packaging

One of the most common viral vectors now in use, recombinant lentivirus is the most efficient means of gene delivery in mammalian cells. At Vigene, our experts can identify the best viral vectors for lentivirus production, providing you with a product that’s precisely tailored to your specific needs.

As a retrovirus, lentivirus uses viral reverse transcriptase before integrating into the host genome. However, unlike other retroviruses, lentivirus affects both dividing and non-dividing cells, making it a versatile vector for gene therapy.

Whereas plasmid DNA allows episomal and transient expression of the invading gene in the host cell, recombinant lentiviral vectors can cause permanent expression of that imported gene by integrating it into the host cell’s genome. This makes lentiviral vectors ideal for in vivo gene delivery.

There are a number of reasons why recombinant lentivirus might be well-suited to your needs, including:

● Ability to transduce non-dividing cells
● Able to hold very long sequences
● Edited coding sequences render virus non-immunogenic
● Products integrate into host genome, increasing stability

 

When it comes to lentivirus production for gene therapy, we take care to ensure all safety precautions are taken. As part of our lentivirus packaging process, we delete viral accessory genes while other essential genes are supplied by packaging and envelope plasmids. We also purify lentivirus with sucrose gradient ultracentrifugation, rendering it safe for in vitro and in vivo animal studies.

The Vigene Biosciences lentivirus production process is fully integrated, starting from your custom vector construction through plasmid preparation all the way to lentiviral vector production. Integrating the entire process ensures you receive the best product with the least amount of difficulty, while getting it to you as fast as possible.

 

Plasmid DNA Production

Many techniques in molecular biology require high-quality plasmid DNA. Cloning, virus packaging, protein production, mutagenesis, and transfection and transmutation all rely on plasmid vectors as an essential processing element.

Our plasmid DNA production services provide our clients with the highest-quality plasmid vectors produced at your specified scale and at a fast—and cost-effective—manner. We take production and quality assurance seriously, employing strict quality control standards and manufacturing processes to ensure that the product we provide is uncontaminated and can accommodate a wide variety of experimental uses.

We offer a full range of plasmid manufacturing services, no matter the scale of your needs. We provide plasmid vectors for preclinical research all the way to clinical trials and commercial manufacturing. Our plasmid DNA is ready to be used for pilot studies, cloning, or being packaged as Vigene Biosciences viral vectors.

We also offer cGMP-compliant plasmid DNA services, which include:

● Upstream production
● Downstream purification
● Development
● Large-scale fermentation
● Material segregation
● Full traceability
● Document control

In addition, we offer a comprehensive range of quality control assays, to ensure that the product you receive meets our high standards of quality assurance.

Sign up for the Vigene Newsletter!

Join over 20,000 scientists who receive monthly updates about Vigene news, product releases, and promotions.

How Vigene Biosciences Works for You

At Vigene, we provide vector-based gene delivery services and products for research and clinical applications around the world. We offer several research-grade and cGMP products that comply with FDA and EMA guidelines, such as Adeno-associated virus (AAV) vectors, Adenovirus vectors, Lentivirus vectors, Retrovirus vectors and Plasmids.

All of our integrated plasmid and viral vector production and analytical service offerings are performed at our state-of-the-art facility. With our custom development and manufacturing services, we can provide essential components to scientists around the world, helping them accelerate their research—and make a difference. Our goal at Vigene is to support scientists at all stages of research, from basic inquiry through animal studies, all the way to clinical trials and commercialization.

Research

As part of our commitment to supporting research, Vigene is developing, manufacturing, and distributing state-of-the-art AAV, lentivirus, retrovirus, adenovirus, and plasmid-based reagents, including HHMI/Janelia Research Campus AAV Biosensors.

Clinical Production

In order to meet the needs and expectations of our clinical and commercial clients, Vigene combines proven production technologies with rigorous regulatory-compliant cGMP production to produce superior products that exceed minimum standards for safe use.

We offer both FDA and EMA compliant cGMP production for AAV, lentivirus, adenovirus, retrovirus, and plasmids to customers around the world, including:

● Pharmaceutical companies
● Biotech companies
● Governmental agencies
● Non-profit organizations

 

Our cGMP services are utilized throughout the globe, and because it is our mission to make gene therapy affordable, our services are always priced to help scientists continue to advance their research.

Viral Delivery Guide Revised

Viral Delivery Guide

Not sure which virus to use? Read our Viral Delivery Guide to find out which virus will work best for your specific applications.

Newsroom

February 5, 2021

Maryland Department of Commerce: Vigene Bioscience...

Vigene Biosciences Plans Major Expansion in Montgomery County, Adding up to 245 New Jobs   Global leader in gene therapy […]
November 3, 2020

Vigene Strengthens Management Team with Another Ke...

Vigene Biosciences announces today another key executive addition. Audrey Chang, Ph.D. is appointed as the VP of QC and Analytical Services.
October 12, 2020

Vigene Strengthens Management Team Critical Execut...

Vigene Biosciences announces today an executive addition. Molly McGlaughlin is appointed as Chief Operation Officer.
October 9, 2020

Rznomics Announces Manufacturing Agreement with Vi...

Vigene has entered a contract manufacturing agreement with Rznomics Inc. for its leading pipeline product, RZ-001. RZ-001 is a gene therapy for advanced hepatocellular carcinoma (HCC).
Partnership Vigene and Virovek colors

Vigene partners with Virovek for cGMP BAC-to-AAV production technology

Virovek has granted Vigene an exclusive cGMP license for their proprietary BAC-to-AAV production technology. AAV vectors generated from this scalable and efficient platform have been proven to infect and transduce a myriad of mammalian cell lines in vitro and a broad range of cell types in vivo.

Read More

Explore Resources

Technical Resources

Get the information you need from our guides and safety data sheets.

Explore Technical Resources >

Citations and Testimonials

Find out how scientists are using our products and services.

Explore Reviews, Citations and Testimonials >

FAQs

Have a general or technical question? Start here first.

Explore FAQs >

Contact Us

If you have any questions about our products and services, please contact us to speak with a member of our team. Our scientists are always happy to discuss your project. We can help you decide which viral vectors will work best for you, and we can help you decide what scale of packaging fits your needs.

At Vigene Biosciences, gene therapy is our business, and we’re committed to making the process affordable to everyone. We’re here to help you find the products and services that meet your needs, so you can help make the world a better place, one experiment at a time.

Have questions?

Let’s find the product or service that meets your needs.

Talk to a Scientist